Artiva Biotherapeutics (NASDAQ:ARTV) CEO Fred Aslan Sells 27,116 Shares of Stock

Posted by George Bondi on May 20th, 2026

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) CEO Fred Aslan sold 27,116 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $244,315.16. Following the completion of the transaction, the chief executive officer owned 1,535,082 shares of the company’s stock, valued at $13,831,088.82. The trade was a 1.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $8.55 on Wednesday. The stock has a fifty day moving average price of $8.32 and a two-hundred day moving average price of $5.65. The stock has a market capitalization of $211.36 million, a price-to-earnings ratio of -2.42 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

ARTV has been the topic of several research reports. Cantor Fitzgerald upped their target price on Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Wedbush upped their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Needham & Company LLC upped their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Finally, HC Wainwright upped their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Read Our Latest Analysis on Artiva Biotherapeutics

Institutional Trading of Artiva Biotherapeutics

Several large investors have recently bought and sold shares of ARTV. Citadel Advisors LLC grew its holdings in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics during the fourth quarter valued at $341,000. Jane Street Group LLC acquired a new stake in shares of Artiva Biotherapeutics during the second quarter valued at $67,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $112,000.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.